Delivery Order SPE2DB22D3301-SPE2DB25FZ0VE
- Not listed
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,556,781,412 units of the pharmaceutical product POMALYST 3 MG CAPSULE 100S. The $162,093.60 contract was awarded on April 4, 2022 with a completion date of April 25, 2022. Amerisourcebergen Drug Corp, which has an existing indefinite delivery contract with the Department of Justice Federal...
- Amerisourcebergen Drug Corp has been awarded a firm fixed price delivery order against their indefinite delivery contract with the Defense Logistics Agency (DLA) Troop Support Medical. Valued at $12,084.50, this order is for the supply of 4562914807 POMALYST 4 MG CAPSULE 21S to support DLA medical facilities. Performance will take place at Amerisourcebergen's headquarters in Conshohocken, Pennsylvania, with completion by December 18, 2023. No set-aside designation was applied to this award. As a...
- This federal contract award from the Defense Logistics Agency (DLA) was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,236.98 fixed-price delivery order contract is for the supply of POMALYST 3 MG CAPSULE 21S, a specialty medication. The contract has an ultimate completion date of May 11, 2023 and was awarded on April 20, 2023. This contract is not designated as a set-aside and is part of a larger $999,999,999 Indefinite...
- This federal contract award, valued at $36,698.28, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office Division. The contract is for the delivery of POMALYST 3 MG CAPSULE 21S, a pharmaceutical product, with a completion date of May 14, 2024. AmerisourceBergen, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, holds a large Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued up...
- This federal contract award, with ID SPE2DB22D3301|SPE2DB25FY0EA, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $23,971.00, is a Firm Fixed Price Delivery Order for the supply of POMALYST 2 MG CAPSULE 21S medication. The award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The $12,287.90 firm-fixed-price delivery order is for the supply of POMALYST 2 MG CAPSULE 21S, a prescription medication. The contract has an ultimate completion date of May 13, 2024. Amerisourcebergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle...
- This federal contract award, valued at $23,971.00, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the supply of POMALYST 2 MG CAPSULE 21S, a specialty pharmaceutical product, with a period of performance through February 20, 2025. This contract is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is a delivery order worth $22,938.76 to provide 4564977355 POMALYST 2 MG CAPSULE 21S to the Defense Logistics Agency (DLA). The award is not set aside and is a firm fixed-price contract with a completion date of July 15, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued up to $999,999,999.00 through December 31, 2025, which serves as the primary...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Paxlovid 300-100 mg dose packs in quantities of 30 units. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $20,945.82 and is scheduled for completion by September 9, 2025. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99...
- AmerisourceBergen Drug Corp was awarded a delivery order on September 9, 2025, by the Defense Logistics Agency's Medical Supply Chain to supply Paxlovid 300-100 mg dose packs in quantities of 30 units. The contract is competitively awarded without any set-aside designation and operates under a firm fixed-price structure with a ceiling value of $7,701.98. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of September 10, 2025. This delivery...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FZ0VEDelivery Order
The Defense Logistics Agency awarded a $13,851.75 delivery order to AmerisourceBergen Drug Corp for Pomalyst 4 mg capsules (21-count packages) on September 11, 2025, with an ultimate completion date of October 2, 2025. This is a firm fixed price contract with no set-aside designation, competitively awarded to the prime contractor's Corporate Office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999 global pharmaceutical support vehicle running through December 2026 that enables the company to supply pharmaceuticals and medical supplies to military healthcare programs worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor headquartered in Pennsylvania that serves as a critical vendor for federal medical procurement, particularly supporting Defense Health Agency and other military healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to deliver a comprehensive range of pharmaceutical products including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains through competitively awarded contracts. This Pomalyst order represents one of numerous delivery orders executed against the broader SPE2DX indefinite delivery contract that provides flexible pharmaceutical support to federal healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.9k | 9/11/25 |